Optimising Hip Mobility, Hamstring Flexibility and Performance Using Lightback

February 5, 2025 updated by: JORGE VELAZQUEZ SAORNIL, Universidad Católica de Ávila

Optimising Hip Mobility, Hamstring Flexibility and Performance in Elite Sprint and Hurdles Athletes Using Lightback: an Experimental Pilot Study

In athletics, in the sprint and hurdles disciplines, muscle injuries account for a significant proportion of injuries. The hamstrings are particularly vulnerable, accounting for between 12% and 26% of all injuries in these sports. A single-blind study was conducted on 20 hurdler patients with the intention of assessing hip mobility, hamstring flexibility and performance. To collect this data, the research team will conduct examinations and interviews with the athletes in two groups: an experimental group using LightBack and a placebo group.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Spain
      • Salamanca, Spain, 27005
        • Recruiting
        • Universidad Pontificia de Salamanca
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Sprinters and hurdlers aged 18 to 30 years.
  • No history of recent (less than 6 months) hamstring or hip injury.
  • Signed informed consent.

Exclusion Criteria:

  • Cruciate or hamstring tears less than 6 months old;
  • Hip and back surgery less than 3 months old;
  • Chronic or acute back problems;
  • Pregnancy;
  • Osteoporosis
  • Tumours, bone cancer of the hip and pelvis;
  • Direct trauma to the back of the thigh less than 6 months old.
  • Orthopaedic or neurological pathologies affecting mobility or muscle activation.
  • Participation in another specific training protocol

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: LIGHTBACK Gropu
This group will perform a standard 20-minute warm-up, and in addition to their usual warm-up, the LIGHTBACK protocol is included.
Device: LIGHTBACK
This group will perform a standard 20-minute warm-up, and the LIGHTBACK protocol is also included.
Placebo Comparator: Placebo Group
This group will perform a standard 20-minute warm-up, but the LIGHTBACK protocol is not included and a similar placebo is used.
Device: Placebo
This group will perform a standard 20-minute warm-up, but the LIGHTBACK protocol is not included and a similar placebo is used.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
hip mobility
Time Frame: 5 weeks
measurement of hip mobility measured by goniometry
5 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
hamstring flexibility
Time Frame: 5 weeks
hamstring flexibility measured with inclinometer, in degrees
5 weeks
performance
Time Frame: 5 weeks
It is a numerical result achieved within the jumping tests: contamovement jump (CMJ): It shall be measured using a force platform with an HD system, which ensures accurate data collection. 0 minimum, 100 maximum.
5 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Universidad Católica de Ávila

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 31, 2025

Primary Completion (Estimated)

March 31, 2025

Study Completion (Estimated)

June 30, 2025

Study Registration Dates

First Submitted

January 31, 2025

First Submitted That Met QC Criteria

February 5, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 5, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 31/01/2025

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Injury;Sports

Clinical Trials on LIGHTBACK

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe